Volume Alert - BMY 58.46 Bristol-Myers Squibb Company $BMY Hit a high today of 58.81 Closing the day 11/06/14 at 58.46 +0.64 +1.11% With a day low of 57.52 and a total volume of 9,610,792.
BMY Recent Posts: http://investorshangout.com/Bristol-Myers-Squ...BMY-50337/
BMY Bristol-Myers Squibb Company Recent Headline News
Final Glance: Pharmaceuticals companies
AP - Thu Nov 06, 6:13PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 1.11% Gain
Comtex SmarTrend(R) - Thu Nov 06, 3:43PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $57.52 to a high of $58.81. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $58.77 on volume of 9.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMY: 58.46 (+0.64)
Bristol-Myers Squibb Set to Possibly Pullback After Yesterday's Rally of 1.11%
Comtex SmarTrend(R) - Thu Nov 06, 3:42PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $57.52 to a high of $58.81. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $58.77 on volume of 9.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMY: 58.46 (+0.64)
Midday Glance: Pharmaceuticals companies
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
Early Glance: Pharmaceuticals companies
AP - Thu Nov 06, 9:51AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries
PR Newswire - Thu Nov 06, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline PLC (NYSE: GSK), Eli Lilly and Company (NYSE: LLY), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, November 05, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,484.53, up 0.58% and the NASDAQ Composite closed at 4,620.72, down 0.06%. The S&P 500 finished the session 0.57% higher at 2,023.57. During the trading session, nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, whereas the index has gained 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
TEVA: 58.72 (+0.93), LLY: 66.96 (-0.03), ABBV: 62.71 (+0.17), GSK: 44.75 (-0.39), BMY: 58.46 (+0.64)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.04 (unch), INCY: 68.40 (+0.68), ONTX: 4.78 (-0.02), BMY: 58.46 (+0.64), GSK: 44.75 (-0.39), STML: 14.57 (-0.09), SNTA: 2.86 (+0.02), KBIO: 1.62 (+0.07), BPTH: 2.98 (+0.01), CELGZ: 3.28 (-0.27), NVS: 92.03 (-0.60)
Why Bristol-Myers Squibb Co. Leaped 15% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 7:46AM CST
BMY data by YCharts What: Shares of big pharma giant Bristol-Myers Squibb shot higher by 15% in October, according to data from S&P Capital IQ , after the company reported better than expected third-quarter earnings results and...
PFE: 30.04 (unch), AZN: 72.85 (-0.62), BMY: 58.46 (+0.64)
Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors
PR Newswire - Wed Nov 05, 7:35AM CST
Protagonist Therapeutics, Inc. today announced that Chaitan Khosla, Ph.D., founder of Alvine Pharmaceuticals and Kosan Biosciences (now part of Bristol-Myers Squibb), Director of Stanford ChEM-H, and Stanford University Professor in the Departments of Chemistry and Chemical Engineering, has been elected to the Protagonist Board of Directors.
BMY: 58.46 (+0.64)
Bristol-Myers Signs Option Deal to Acquire Galecto Biotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:30PM CST
Bristol-Myers Squibb Company (BMY) and Denmark-based Galecto Biotech AB announced that both companies have entered into an agreement whereby Bristol-Myers Squibb will have an exclusive option to acquire Galecto Biotech AB.
AGN: 197.40 (+1.08), ABBV: 62.71 (+0.17), TEVA: 58.72 (+0.93), BMY: 58.46 (+0.64)
Lexicon Strengthens Clincial Operations And Commercial Readiness
PR Newswire - Tue Nov 04, 3:15PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today management additions directed towards the completion of Phase 3 development and commercial preparations for telotristat etiprate in carcinoid syndrome and preparation for Phase 3 initiation and commercial readiness for sotagliflozin (LX4211) in type 1 diabetes.
LXRX: 1.48 (+0.03), BMY: 58.46 (+0.64)
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference
Business Wire - Tue Nov 04, 9:00AM CST
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Credit Suisse Annual Health Care Conference on Tuesday, November 11, 2014 in Phoenix. Charles Bancroft, executive vice president and chief financial officer, will make a formal presentation about the company at 8:30 a.m. MST (10:30 a.m. EST).
BMY: 58.46 (+0.64)
Insider Trading Research for Micron, Bristol-Myers Squibb, Twitter, American Realty Capital Properties, Plug Power, and GoPro
PR Newswire - Mon Nov 03, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Micron (NASDAQ:MU), Bristol-Myers Squibb (NYSE:BMY), Twitter (NYSE:TWTR), American Realty Capital Properties (NASDAQ:ARCP), Plug Power (NASDAQ
LUG), and GoPro (NASDAQ:GPRO).
GPRO: 78.76 (+2.87), MU: 33.35 (-0.36), PLUG: 5.12 (+0.16), ARCP: 8.64 (-0.07), BMY: 58.46 (+0.64), TWTR: 40.84 (+0.47)
Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis
Business Wire - Mon Nov 03, 7:30AM CST
Bristol-Myers Squibb Company (NYSE:BMY) and Galecto Biotech AB today announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions. Total aggregate payments under the agreement have the potential to reach $444 million, which includes the option fee, an option exercise fee and subsequent clinical and regulatory milestone payments.
BMY: 58.46 (+0.64)
Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 94.55 (+1.05), AGN: 197.40 (+1.08), ACT: 250.38 (+2.47), BMY: 58.46 (+0.64)
BMY Recent Posts: http://investorshangout.com/Bristol-Myers-Squ...BMY-50337/
BMY Bristol-Myers Squibb Company Recent Headline News
Final Glance: Pharmaceuticals companies
AP - Thu Nov 06, 6:13PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 1.11% Gain
Comtex SmarTrend(R) - Thu Nov 06, 3:43PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $57.52 to a high of $58.81. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $58.77 on volume of 9.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMY: 58.46 (+0.64)
Bristol-Myers Squibb Set to Possibly Pullback After Yesterday's Rally of 1.11%
Comtex SmarTrend(R) - Thu Nov 06, 3:42PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $57.52 to a high of $58.81. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $58.77 on volume of 9.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMY: 58.46 (+0.64)
Midday Glance: Pharmaceuticals companies
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
Early Glance: Pharmaceuticals companies
AP - Thu Nov 06, 9:51AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries
PR Newswire - Thu Nov 06, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline PLC (NYSE: GSK), Eli Lilly and Company (NYSE: LLY), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, November 05, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,484.53, up 0.58% and the NASDAQ Composite closed at 4,620.72, down 0.06%. The S&P 500 finished the session 0.57% higher at 2,023.57. During the trading session, nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, whereas the index has gained 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
TEVA: 58.72 (+0.93), LLY: 66.96 (-0.03), ABBV: 62.71 (+0.17), GSK: 44.75 (-0.39), BMY: 58.46 (+0.64)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.04 (unch), INCY: 68.40 (+0.68), ONTX: 4.78 (-0.02), BMY: 58.46 (+0.64), GSK: 44.75 (-0.39), STML: 14.57 (-0.09), SNTA: 2.86 (+0.02), KBIO: 1.62 (+0.07), BPTH: 2.98 (+0.01), CELGZ: 3.28 (-0.27), NVS: 92.03 (-0.60)
Why Bristol-Myers Squibb Co. Leaped 15% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 7:46AM CST
BMY data by YCharts What: Shares of big pharma giant Bristol-Myers Squibb shot higher by 15% in October, according to data from S&P Capital IQ , after the company reported better than expected third-quarter earnings results and...
PFE: 30.04 (unch), AZN: 72.85 (-0.62), BMY: 58.46 (+0.64)
Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors
PR Newswire - Wed Nov 05, 7:35AM CST
Protagonist Therapeutics, Inc. today announced that Chaitan Khosla, Ph.D., founder of Alvine Pharmaceuticals and Kosan Biosciences (now part of Bristol-Myers Squibb), Director of Stanford ChEM-H, and Stanford University Professor in the Departments of Chemistry and Chemical Engineering, has been elected to the Protagonist Board of Directors.
BMY: 58.46 (+0.64)
Bristol-Myers Signs Option Deal to Acquire Galecto Biotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:30PM CST
Bristol-Myers Squibb Company (BMY) and Denmark-based Galecto Biotech AB announced that both companies have entered into an agreement whereby Bristol-Myers Squibb will have an exclusive option to acquire Galecto Biotech AB.
AGN: 197.40 (+1.08), ABBV: 62.71 (+0.17), TEVA: 58.72 (+0.93), BMY: 58.46 (+0.64)
Lexicon Strengthens Clincial Operations And Commercial Readiness
PR Newswire - Tue Nov 04, 3:15PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today management additions directed towards the completion of Phase 3 development and commercial preparations for telotristat etiprate in carcinoid syndrome and preparation for Phase 3 initiation and commercial readiness for sotagliflozin (LX4211) in type 1 diabetes.
LXRX: 1.48 (+0.03), BMY: 58.46 (+0.64)
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference
Business Wire - Tue Nov 04, 9:00AM CST
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Credit Suisse Annual Health Care Conference on Tuesday, November 11, 2014 in Phoenix. Charles Bancroft, executive vice president and chief financial officer, will make a formal presentation about the company at 8:30 a.m. MST (10:30 a.m. EST).
BMY: 58.46 (+0.64)
Insider Trading Research for Micron, Bristol-Myers Squibb, Twitter, American Realty Capital Properties, Plug Power, and GoPro
PR Newswire - Mon Nov 03, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Micron (NASDAQ:MU), Bristol-Myers Squibb (NYSE:BMY), Twitter (NYSE:TWTR), American Realty Capital Properties (NASDAQ:ARCP), Plug Power (NASDAQ
LUG), and GoPro (NASDAQ:GPRO). GPRO: 78.76 (+2.87), MU: 33.35 (-0.36), PLUG: 5.12 (+0.16), ARCP: 8.64 (-0.07), BMY: 58.46 (+0.64), TWTR: 40.84 (+0.47)
Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis
Business Wire - Mon Nov 03, 7:30AM CST
Bristol-Myers Squibb Company (NYSE:BMY) and Galecto Biotech AB today announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions. Total aggregate payments under the agreement have the potential to reach $444 million, which includes the option fee, an option exercise fee and subsequent clinical and regulatory milestone payments.
BMY: 58.46 (+0.64)
Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 94.55 (+1.05), AGN: 197.40 (+1.08), ACT: 250.38 (+2.47), BMY: 58.46 (+0.64)
